UF links PIK3CA mutations to immune disruption in canine HSA

Canine hemangiosarcoma research at the University of Florida is sharpening the field’s view of how one of the most aggressive canine cancers may be driven, and potentially targeted. In work highlighted by UF in January 2025, investigators linked activating PIK3CA mutations in canine hemangiosarcoma to disrupted immune signaling, showing that mutant tumor cells don’t just grow aggressively, but also appear to reshape the tumor microenvironment by recruiting or influencing surrounding healthy cells and promoting cytokine programs tied to immune confusion. The findings build on a recent Cancer Gene Therapy paper from the same group and add to a growing body of evidence that canine hemangiosarcoma can serve as a comparative model for rare human angiosarcoma. (vetmed.ufl.edu)

Why it matters: For veterinary professionals, the study adds biologic rationale for moving beyond a one-size-fits-all view of hemangiosarcoma. UF reports that hemangiosarcoma remains hard to detect early and carries poor outcomes, while prior genomic work has shown PIK3CA is a recurrent mutation in this disease. More recent real-world evidence suggests dogs with PIK3CA-mutant tumors may derive particular benefit from regimens that include targeted therapy, especially mTOR-directed approaches, reinforcing the clinical value of molecular profiling as precision oncology becomes more practical in referral settings. (vetmed.ufl.edu)

What to watch: The next step is whether these mechanistic findings translate into prospective trials, biomarker-guided treatment selection, or combination strategies that target both PIK3CA signaling and the tumor immune niche. (vetmed.ufl.edu)